Uveal melanoma is a rare but highly aggressive form of melanoma that originates in the uvea, the middle vascular layer of the eye composed of three main parts: the iris, the ciliary body, and the choroid. The choroid is the most common site for uveal melanoma, followed by the ciliary body and then the iris. Despite accounting for only a small percentage of all melanomas, uveal melanoma is the most common primary intraocular cancer in adults and carries significant mortality risk, especially due to its tendency to metastasize, most frequently to the liver but also to the lungs, bones, and skin. The staging of uveal melanoma is based on tumor size, degree of local invasion, involvement of adjacent ocular structures, regional lymph node involvement, and distant metastasis. Stage 0, or in situ melanoma, indicates the tumor is confined to the inner layers of the eye and has not spread beyond the uvea. Stage I involves a small to medium-sized tumor localized strictly within the uvea without extension to surrounding tissues or distant organs, allowing for effective early treatment. Stage II is characterized by a larger or more locally aggressive tumor that may invade adjacent tissues such as the sclera (the white outer coat of the eye) or the optic nerve, though still primarily confined to the eye. Stage III denotes regional spread beyond the eye, including involvement of nearby lymph nodes or adjacent ocular and orbital structures, often necessitating more aggressive therapeutic approaches. Stage IV represents metastatic disease with tumor cells having disseminated to distant organs, most notably the liver, which is the predominant site of metastasis, but also to other sites like the lungs, bones, and skin. At this stage, prognosis is poor, and treatment shifts focus from curative intent to management of metastasis and prolongation of survival, given the aggressive and often refractory nature of metastatic uveal melanoma.

Uveal melanoma risk factors encompass a variety of genetic, environmental, and physiological elements, though the precise causes remain incompletely understood. Age plays a significant role, with most diagnoses occurring between ages 50 and 70, although younger individuals can also be affected. Eye color is another important factor, as people with light-colored eyes blue, green, or gray are at greater risk due to lower melanin levels, which offer less protection from ultraviolet (UV) radiation. Similarly, individuals with fair skin or a history of sunburns may have a heightened risk, although the link between UV exposure and uveal melanoma is less direct compared to skin melanoma. Genetic predisposition is critical, especially mutations in the BAP1 gene, which have been linked to increased susceptibility to uveal and other ocular cancers. The presence of an ocular nevus, particularly if large or atypical, raises the risk of malignant transformation into uveal melanoma. Family history of uveal melanoma or other melanoma types further elevates the risk, suggesting inherited genetic components. Additionally, rare eye conditions like ocular melanocytosis characterized by abnormal pigmentation in the eye are associated with increased melanoma risk. Collectively, these factors highlight the multifactorial nature of uveal melanoma risk, emphasizing the need for vigilance in individuals with these predisposing characteristics.

Uveal melanoma often develops silently, with no noticeable symptoms in its early stages, and is frequently detected incidentally during routine eye examinations. When symptoms do manifest, they typically relate to the tumors impact on the eyes structures and vision. Patients may experience blurred or distorted vision in the affected eye, especially if the tumor interferes with the retina or optic nerve function. Visual field loss, such as blind spots or reduced peripheral vision, can also occur as the tumor grows. Some individuals report seeing flashes of light or floaters small, moving spots or shapes in their vision, which result from the tumors presence within the eye. Eye pain is uncommon unless the melanoma extends beyond the uveal tract, but some patients might experience discomfort or a sensation of pressure. In rare cases, physical changes to the eye may be observed, including alterations in iris color or shape, or an irregularly shaped pupil, signaling more advanced disease or tumor involvement of the anterior structures of the eye. These symptoms warrant prompt ophthalmologic evaluation to enable early diagnosis and treatment.

Diagnosing uveal melanoma involves a comprehensive approach that starts with a thorough eye examination by an ophthalmologist, who uses tools such as a slit-lamp and dilated fundus exam to visually inspect the internal structures of the eye for abnormalities. To further characterize the tumor, ocular ultrasound is employed to assess the size, shape, and precise location of the lesion within the eye. Fluorescein angiography involves injecting a fluorescent dye into the bloodstream, allowing specialized cameras to track blood flow in the eye and detect vascular changes indicative of melanoma. Optical Coherence Tomography (OCT) provides high-resolution cross-sectional images of the retina and adjacent tissues, helping to determine the tumor's impact on retinal integrity. Although not routinely performed, a fine needle aspiration biopsy may be conducted in select cases to obtain tissue samples for histopathological confirmation of melanoma. Genetic testing, particularly for mutations in the BAP1 gene, plays a crucial role in prognosis and tailoring treatment strategies. Additionally, to evaluate potential metastasis most commonly to the liver advanced imaging modalities such as CT scans, MRI, or PET scans are utilized, enabling comprehensive staging and guiding therapeutic decisions.

Treatment of uveal melanoma is tailored to the tumors size, location, and metastatic status, involving several key approaches. Surgery remains a cornerstone, with enucleation the complete removal of the affected eye reserved for large tumors or cases with a high risk of metastasis. For smaller, well-localized tumors not involving critical structures, tumor resection may be an option to preserve the eye and some vision. Radiation therapy plays a vital role, particularly plaque brachytherapy, where radioactive seeds are placed directly on the tumor to deliver targeted radiation while sparing healthy tissue. Advanced radiation techniques like proton beam therapy and gamma knife radiosurgery offer precise tumor targeting with minimal collateral damage. Laser therapies, such as laser photocoagulation, may be used to selectively destroy tumor cells in certain cases. Although chemotherapy generally shows limited effectiveness against uveal melanoma, it may be considered for metastatic disease. Immunotherapy, including immune checkpoint inhibitors like pembrolizumab, is an emerging area of research for treating metastatic cases, though results remain under investigation. Given that the liver is the most frequent site of metastasis, liver-directed treatments such as surgical resection or ablative therapies are employed when metastases are confined, aiming to control disease progression and prolong survival.

Although there is no guaranteed way to prevent uveal melanoma, several strategies can help reduce the risk and facilitate early detection, which is critical for improving outcomes. Regular, comprehensive eye examinations by an ophthalmologist are essential, particularly for individuals with known risk factors such as a family history of uveal melanoma, presence of ocular nevi, or genetic mutations like those in the BAP1 gene. These exams allow for early identification of suspicious lesions before they progress to advanced stages. While uveal melanoma is not definitively linked to ultraviolet (UV) radiation exposure in the same way as cutaneous melanoma, wearing UV-protective sunglasses is still recommended as a precautionary measure to shield the eyes from potential UV-related damage that could contribute to ocular health issues. Genetic counseling plays a critical role for individuals with inherited predispositions; through genetic testing and counseling, at-risk individuals can receive personalized monitoring plans, early intervention options, and guidance on symptom vigilance. Minimizing other risk factors, such as avoiding unnecessary radiation exposure to the head and eyes, may also contribute to reducing risk. Together, these preventive approaches emphasize vigilance, protection, and early detection as key components in managing the risk of developing uveal melanoma.

ngoing research in uveal melanoma is intensely focused on uncovering the genetic mechanisms that drive the disease, enhancing early detection methods, and developing more effective treatment options. Genetic research aims to identify new mutations beyond known ones, such as those in the BAP1 gene, to better understand how uveal melanoma develops and progresses, which can lead to novel therapeutic targets. Immunotherapy, particularly the use of immune checkpoint inhibitors, is being actively investigated as a promising approach for advanced or metastatic uveal melanoma, a form of cancer traditionally resistant to conventional treatments like chemotherapy and radiation. Additionally, advances in personalized medicine, driven by comprehensive genetic profiling of tumors, hold the potential to revolutionize patient care by tailoring treatments to the unique genetic characteristics of each tumor, improving effectiveness and minimizing unnecessary side effects. This integrative research approach aims not only to improve survival rates but also to enhance quality of life for patients with uveal melanoma.

1. How common is uveal melanoma? Uveal melanoma is rare, with an estimated incidence of about 5-6 cases per million people per year worldwide. It is the most common primary intraocular cancer in adults. 2. Can uveal melanoma spread? Yes, uveal melanoma can spread to other parts of the body, especially the liver. This metastasis can significantly impact prognosis. 3. What are the survival rates for uveal melanoma? The survival rate for localized uveal melanoma is high, with around 80-90% survival at 5 years. However, the survival rate drops significantly once the cancer has metastasized, especially to the liver. 4. Is uveal melanoma related to skin melanoma? Although both are melanomas, uveal melanoma is not directly related to skin melanoma. It originates from a different type of melanocyte in the eye and is not caused by UV exposure, though both share some common genetic factors. 5. Can uveal melanoma be prevented? While there are no known methods to prevent uveal melanoma, early detection through regular eye exams, especially for those at high risk, can improve treatment outcomes.